Gilead to Initiate P-II/III Study Evaluating Remdesivir in Pediatric Patients Hospitalized With COVID-19

 Gilead to Initiate P-II/III Study Evaluating Remdesivir in Pediatric Patients Hospitalized With COVID-19

Gilead to Initiate P-II/III Study Evaluating Remdesivir in Pediatric Patients Hospitalized With COVID-19

Shots:

  • Gilead will begin enrollment in P-II/III clinical trial assessing the safety, tolerability, PK and efficacy of remdesivir in ~50 pediatric patients with moderate-to-severe COVID-19, including newborns through adolescents
  • The trial will be conducted at 30+ sites in the US and EU. Remdesivir is available to pediatric patients with severe COVID-19 under our compassionate use program since Feb’2020 as well as under the US FDA’s EUA
  • Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity both in vitro / in vivo in animal models against multiple emerging viral pathogens, including Ebola, Marburg, MERS and SARS

Click here to read full press release/ article | Ref: Gilead | Image: Scrip-Informa

Related News: EMA to Grant Initial Authorization to Gilead’s Remdesivir for COVID-19 is Imminent

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post